Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease

Blood

Volumn 86, Issue 12, 1995, Pages 4422-4429

  Pan, Luying ^a   Delmonte Jr , John ^a   Jalonen, Candice K ^a   Ferrara, James L M ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; COLONY STIMULATING FACTOR RECEPTOR; CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL POLARITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION;

EID: 0028843985     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v86.12.4422.bloodjournal86124422     Document Type: Article

References (43)

1. Bronchud MH: Recombinant human granulocyte colony-stimulating factor in the management of cancer patients: Five years on. Oncology 51:189, 1994
2. Demetri GD, Griffin JD: Granulocyte colony-stimulating factor and its receptor. Blood 78:2791, 1991
3. Tkatch LS, Tweardy DJ: Human granulocyte colony-stimulating factor (G-CSF), the premier granulopoietin: Biology, clinical utility, and receptor structure and function. Lymphokine Cytokine Res 12:477, 1993
4. Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M, Mealiffe M, Terstappen LWMM, Hardwick A, Moubayed M, Oldham F, Corringham RET, Ho A: Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocytes-macrophage colony-stimulating factor (GM-CSF) or G-CSF: Potential role in allogeneic marrow transplantation. Blood 85:275, 1995
5. Weaver CH, Longin K, Buckner CD, Bensinger W: Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 13:411, 1994
6. Dreger P, Suttorp M, Haferlach T, Loffler H, Schmitz N: Allogeneic granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 81:1404, 1993
7. Russell NH, Hunter A, Rogers S, Hanley J, Anderson D: Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet 341:1482, 1993
8. Sasaki A, Tsukaguchi M, Hirai M, Ohira H, Nakao Y, Yamane T, Park K, Im T, Tatsumi N: Transplantation of allogeneic peripheral blood stem cells after myeloablative treatment of a patient in blastic crisis of chronic myelocytic leukemia. Am J Hematol 47:45, 1994
9. Molina L, Chabannon C, Viret F, Moine A, Nicolini F, Hollard D, Sotto J-J: Granulocyte colony-stimulating factor-mobilized allogeneic peripheral blood stem cells for rescue graft failure after allogeneic bone marrow transplantation in two patients with acute myeloblastic leukemia in first complete remission. Blood 85:1678, 1995
10. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85:1655, 1995
11. Korbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, Andreeff M, Champlin R: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allograft. Blood 85:1659, 1995
12. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H, Hunter A, Russell NH: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by Filgrastim (granulocyte colony-stimulating factor). Blood 85:1666, 1995
13. Mowat A: Antibodies to IFN-gamma prevent immunological mediated intestinal damage in murine graft-versus-host reactions. Immunology 68:18, 1989
14. Antin JH, Ferrara JLM: Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964, 1992
15. Nestel FP, Price KS, Seemayer TA, Lapp WS: Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175:405, 1992
16. Vogelsgang GB, Hess AD: Graft-versus-host disease: New directions for a persistent problem. Blood 84:2061, 1994
17. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE: Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 84:3540, 1994
18. + donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 155:585, 1995
19. + cells. J Immunol 155:2396, 1995
20. Mosmann TR, Coffman RL: TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145, 1989
21. Swain SL, Bradley LM, Croft M, Tonkonogy S, Atkins G, Weinberg AD, Duncan DD, Hedrick SM, Dutton RW, Huston G: Helper T-cell subsets: Phenotype, function and the role of lymphokines in regulating their development. Immunol Rev 123:115, 1991
22. Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, Bloom BR: Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254:279, 1991
23. Finkelman FD: Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease. J Exp Med 182:279, 1995
24. + T helper type 2 cells. J Exp Med 181:5, 1995
25. Croft M, Carter L, Swain SL, Dutton RW: Generation of antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 180:1715, 1994
26. Morse HC, Shen FW, Hammerling U: Genetic nomenclature for loci controlling mouse lymphocyte antigens. Immunogenetics 25:71, 1987
27. Brummer E: Immunological activation of polymorphonuclear neutrophils for fungal killing: studies with murine cells and blastomyces dermatitis in vitro. J Leukoc Biol 36:505, 1984
28. + cells. J Exp Med 180:307, 1994
29. Kelso A: Th1 and Th2 subsets: Paradigms lost? Immunol Today 16:374, 1995
30. + T lymphocytes. Science 268:863, 1995
31. Ferrara JLM: The cytokine storm of acute graft-versus host disease. Haematol Rev 8:27, 1994
32. Aoki Y, Hiromatsu K, Kobayashi N, Hotta T, Saito H, Igarashi H, Niho Y, Yoshikai Y: Protective effect of granulocyte colony-stimulating factor against T-cell-mediated lethal shock triggered by superantigens. Blood 86:1420, 1995
33. Ohsaka A, Saionji K, Kuwaki T, Takeshima T, Igari J: Granulocyte colony-stimulating factor administration modulates the surface expression of effector cell molecules on human monocytes. Br J Haematol 89:465, 1995
34. Gorgen I, Hartung T, Leist M, Niehorster M, Tiegs G, Uhlig S, Weitzel F, Wendel A: Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-α. J Immunol 149:918, 1992
35. Hartung T, Docke WD, Grabtner F, Krieger G, Sauer A, Stevens P, Volk HD, Wendel A: Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 85:2482, 1995
36. Piguet PF, Grau GE, Allet B, Vassalli PJ: Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 166:1280, 1987
37. Holler E, Kolb HJ, Moller A, Kempeni J, Lisenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C, Ledderose G, Brehm G, Mittermuller J, Wilmanns W: Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75:1011, 1990
38. McCarthy PL, Abhyankar S, Neben S, Newman G, Sieff C, Thompson RC, Burakoff SJ, Ferrara JLM: Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78:1915, 1991
39. Holler E, Kolb HJ, Hintermeier-Knabe R, Mittermuller J, Thierfelde S, Kaul M, Wilmanns W: The role of tumor necrosis factor α in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 25:1234, 1993
40. Abhyankar S, Gilliland DG, Ferrara JLM: Interleukin 1 is a critical effector molecule during cytokine dysregulation in graft-versus-host disease to minor histocompatibility antigens. Transplantation 53:1518, 1993
41. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down regulated by tumor necrosis factor α. J Exp Med 179:1109, 1994
42. Mckenzie JL, Calder VL, Starling GC, Hart DNJ: Role of tumour necrosis factor-alpha in dendritic cell mediated primary mixed leucocyte reaction. Bone Marrow Transplant 15:163, 1995
43. Sallusto F, Cella M, Danieli C, Lanzavecchia A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: down regulation by cytokines and bacterial products. J Exp Med 181:389, 1995